NARI Pengajuan SEC - Inari Medical, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	254900K1GAHHPGQGTS83
CIK	1531048

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inari Medical, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

March 3, 2025	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39293 Inari Medical, Inc. (Exact name of registrant as specified in its
February 19, 2025	EX-3.2	AMENDED AND RESTATED INARI MEDICAL, INC. ARTICLE I. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INARI MEDICAL, INC. ARTICLE I. OFFICES Section 1. Registered Office. The registered office of Inari Medical, Inc., (the “Corporation”) in the State of Delaware shall be located at such location as stated in the Certificate of Incorporation of the Corporation, which may be changed from time to time. Section 2. Special Meetings. The Corporation may also hav
February 19, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 19, 2025 S-8 POS As filed with the Securities and Exchange Commission on February 19, 2025 Registration No.
February 19, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 19, 2025 S-8 POS As filed with the Securities and Exchange Commission on February 19, 2025 Registration No.
February 19, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 19, 2025 As filed with the Securities and Exchange Commission on February 19, 2025 Registration No.
February 19, 2025	EX-99.(A)(5)(C)	1 Exhibit (a)(5)(C) February 19, 2025 Press release Stryker completes acquisition of Inari Medical, Inc.
February 19, 2025	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION INARI MEDICAL, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INARI MEDICAL, INC. FIRST: The name of the corporation (which is hereinafter referred to as the “Corporation”) is Inari Medical, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is The Corporation Trust Center, 1209 Orange Street in the City of Wilmington, County of New Castle, Delaware 19801.
February 19, 2025	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Inari Medical, Inc. (Name of Subject Company (Issue UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger Sub, Inc. (Name of Filing Person (Offeror)) A wholly owned subsidiary of Stryker Corporation (Name of Filing Person (Parent of Offe
February 19, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 19, 2025 As filed with the Securities and Exchange Commission on February 19, 2025 Registration No.
February 19, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 19, 2025 As filed with the Securities and Exchange Commission on February 19, 2025 Registration No.
February 19, 2025	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number
February 19, 2025	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F
February 19, 2025	POSASR	As filed with the Securities and Exchange Commission on February 19, 2025 As filed with the Securities and Exchange Commission on February 19, 2025 Registration No.
February 14, 2025	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number
February 14, 2025	EX-99.(A)(5)(K)	Stryker Acquisition: Purchase of Inari Shares Exhibit (a)(5)(K) Stryker Acquisition: Purchase of Inari Shares FAQs 1. What will happen to my stock at the close of the acquisition? See below chart for the different equity vehicles and how they will be processed. Owned or Purchased Shares (i.e. shares previously received upon settlement of equity awards or purchased under the ESPP) Unvested RSUs and PSUs will be cancelled in exchange for cash U
February 7, 2025	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number
February 6, 2025	EX-99.(A)(5)(J)	Team Purple – Exhibit (a)(5)(J) Team Purple – We are writing to address some questions we have received related to the pending acquisition of Inari by Stryker, which was announced on January 6, 2025.
February 6, 2025	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number
February 4, 2025	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Inari Medical, Inc. (Name of Subject Company (Issue UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger Sub, Inc. (Name of Filing Person (Offeror)) A wholly owned subsidiary of Stryker Corporation (Name of Filing Person (Parent of Offe
February 4, 2025	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number
January 17, 2025	EX-99.(A)(1)(E)	Offer to Purchase for Cash All Outstanding Shares of Common Stock Inari Medical, Inc. $80.00 per share in cash pursuant to the Offer to Purchase dated January 17, 2025 Eagle 1 Merger Sub, Inc. a wholly owned subsidiary of Stryker Corporation Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Inari Medical, Inc.
January 17, 2025	SC 14D9	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, In Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company) Inari Medical, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number
January 17, 2025	EX-99.(A)(1)(F)	This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase dated January 17, 2025 and the related Letter of Transmi Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).
January 17, 2025	EX-99.(A)(1)(A)	Offer to Purchase for Cash All Outstanding Shares of Common Stock Inari Medical, Inc. $80.00 per share in cash Eagle 1 Merger Sub, Inc., a wholly owned subsidiary of Stryker Corporation Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Inari Medical, Inc.
January 17, 2025	EX-99.(A)(1)(B)	Letter of Transmittal to Tender Shares of Common Stock INARI MEDICAL, INC. at $80.00 Per Share in Cash Pursuant to the Offer to Purchase dated January 17, 2025 by Eagle 1 Merger Sub, Inc., a wholly owned subsidiary of Stryker Corporation Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of INARI MEDICAL, INC.
January 17, 2025	EX-99.(E)(3)	CONFIDENTIALITY AGREEMENT Exhibit (e)(3) EXECUTION VERSION CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (this “Agreement”), dated as of December 2, 2024, is by and between Stryker Corporation, a Michigan corporation (“Counterparty”), and Inari Medical, Inc.
January 17, 2025	EX-FILING FEES	Calculation of Filing Fee Table SC TO -T (Form Type) INARI MEDICAL, INC. (Name of Subject Company (Issuer)) EAGLE 1 MERGER SUB, INC. (Names of Filing Persons — Offeror) STRYKER CORPORATION (Names of Filing Persons — Parent of Offeror) Table 1—Transac Exhibit 107 Calculation of Filing Fee Table SC TO -T (Form Type) INARI MEDICAL, INC.
January 17, 2025	EX-99.(D)(4)	CLEAN TEAM CONFIDENTIALITY AGREEMENT Exhibit (d)(4) ATTORNEY WORK PRODUCT PRIVILEGED AND CONFIDENTIAL CLEAN TEAM CONFIDENTIALITY AGREEMENT This Clean Team Confidentiality Agreement (the “Agreement”) is entered into this 19th day of December 2024, between Stryker Corporation and all affiliates thereof (“you”, “your” or “Stryker”), and Inari Medical, Inc.
January 17, 2025	EX-99.(A)(1)(C)	NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock Inari Medical, Inc. $80.00 per share in cash pursuant to the Offer to Purchase dated January 17, 2025 Eagle 1 Merger Sub, Inc., a wholly owned subsidiary of Stryker Corporation Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of Inari Medical, Inc.
January 17, 2025	EX-99.(D)(2)	[Signature Pages Follow] Exhibit (d)(2) EXECUTION VERSION JOINDER This JOINDER TO THE AGREEMENT AND PLAN OF MERGER (this “Joinder”), is made and entered into as of January 7, 2025, by Eagle 1 Merger Sub, Inc.
January 17, 2025	EX-99.(D)(3)	CONFIDENTIALITY AGREEMENT Exhibit (d)(3) EXECUTION VERSION CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (this “Agreement”), dated as of December 2, 2024, is by and between Stryker Corporation, a Michigan corporation (“Counterparty”), and Inari Medical, Inc.
January 17, 2025	EX-99.(A)(1)(D)	Offer to Purchase All Outstanding Shares of Common Stock Inari Medical, Inc. $80.00 per share in cash pursuant to the Offer to Purchase dated January 17, 2025 Eagle 1 Merger Sub, Inc. a wholly owned subsidiary of Stryker Corporation Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of Inari Medical, Inc.
January 17, 2025	EX-99.(E)(4)	CLEAN TEAM CONFIDENTIALITY AGREEMENT Exhibit (e)(4) CLEAN TEAM CONFIDENTIALITY AGREEMENT This Clean Team Confidentiality Agreement (the “Agreement”) is entered into this 19th day of December 2024, between Stryker Corporation and all affiliates thereof (“you”, “your” or “Stryker”), and Inari Medical, Inc.
January 17, 2025	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger Sub, Inc. (Name of Filing Person (Offeror)) A wholly owned subsidiary of Stryker Corporation (Name of Filing Person (Parent of Offeror)) Common Stock
January 15, 2025	EX-99.2	Dear Valued Partner – Exhibit 99.2 Dear Valued Partner – On January 6, 2025 we announced that Inari Medical has entered into a definitive agreement to be acquired by Stryker. You can read the press release announcing the transaction linked here. This is an exciting development that will greatly benefit patients, physicians, and hospitals. What will not change is the commitment to our products, clinical trials, physicia
January 15, 2025	EX-99.1	Dear Valued Partner, Exhibit 99.1 Dear Valued Partner, I am reaching out with some exciting news. Recently, we announced that Inari is being acquired by Stryker. You can read the press release we issued announcing the transaction here. We believe that combining Inari’s world-class VTE treatments with Stryker’s capabilities and global footprint will allow us to build on our momentum, enter new markets and further impac
January 15, 2025	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INARI MEDICAL, INC. (Name of Subject Company) IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INARI MEDICAL, INC. (Name of Subject Company) INARI MEDICAL, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number of
January 7, 2025	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INARI MEDICAL, INC. (Name of Subject Company) IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INARI MEDICAL, INC. (Name of Subject Company) INARI MEDICAL, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number of
January 7, 2025	EX-99.2	NARI Transaction Employee FAQ EX-99.2 Exhibit 99.2 NARI Transaction Employee FAQ 1. What was announced? • Inari has entered into an agreement to be acquired by Stryker. The press release announcing the transaction can be found on Inari’s investor relations website. • This transaction marks an exciting next chapter of our Ethos of putting patients first, making no small plans and taking care of each other. • Stryker shares our
January 7, 2025	EX-99.1	Team Purple, EX-99.1 Exhibit 99.1 Team Purple, Today, we announced that Inari Medical has entered an agreement to be acquired by Stryker. Attached is a copy of the press release announcing the transaction. This marks an exciting new chapter of our Ethos of putting patients first, making no small plans and taking care of each other. Combining Inari’s world-class VTE treatments with Stryker’s capabilities and gl
January 7, 2025	EX-99.1	1 EX-99.1 Exhibit 99.1 January 6, 2025 Press release Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment PORTAGE, Mich. and IRVINE, Calif., USA – January 6, 2025 – Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of co
January 7, 2025	EX-99.2	Copyright © 2025 Stryker EX-99.2 Copyright © 2025 Stryker This presentation contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements, including statements regarding the anticipated benefits to Str
January 7, 2025	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Stryker Corporati UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Stryker Corporation (Exact name of Registrant as Specified in Its Charter) Michigan 001-13149 38-1239739 (State or Other Jurisdiction of Incorporation) (Commission Fil
January 7, 2025	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Inari Medical, Inc. (Name of Subject Company (Issuer)) Eagle 1 Merger Sub, Inc. (Offeror) A wholly owned subsidiary of Stryker Corporation (Parent of Offeror) Common Stock, par value $0.001 per share (Title of Class of
January 7, 2025	EX-99.4	Social Media Posts EX-99.4 Exhibit 99.4 Social Media Posts Inari LinkedIn 1.6.25 Inari X / Twitter 1.6.25 Inari Facebook 1.6.25 Inari Instagram 1.6.25 Forward-Looking Statements This communication may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “sho
January 7, 2025	EX-99.3	Dear Valued Customer, EX-99.3 Exhibit 99.3 Dear Valued Customer, Today, we announced that Inari Medical has entered into a definitive agreement to be acquired by Stryker. You can read the press release announcing the transaction here. This is an exciting development that will greatly benefit patients, physicians, and hospitals. What will not change is the commitment to our products, clinical trials, physician support a
January 6, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil
January 6, 2025	EX-2.1	AGREEMENT AND PLAN OF MERGER by and between STRYKER CORPORATION INARI MEDICAL, INC. Dated as of January 6, 2025 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and between STRYKER CORPORATION and INARI MEDICAL, INC. Dated as of January 6, 2025 TABLE OF CONTENTS Page ARTICLE 1 THE OFFER AND MERGER Section 1.1 The Offer 2 Section 1.2 Company Actions 4 Section 1.3 The Merger 5 Section 1.4 Closing 6 Section 1.5 Effective Time 6 Section 1.6 Effects of the Merger 6 Section 1.7 Organizational Documents of the Survivin
January 6, 2025	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INARI MEDICAL, INC. (Name of Subject Company) IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 INARI MEDICAL, INC. (Name of Subject Company) INARI MEDICAL, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number of
January 6, 2025	EX-99.1	1/4 Exhibit 99.1 Source: Stryker Corporation January 06, 2025 16:08 ET Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the iss
November 8, 2024	EX-99	JOINT FILING AGREEMENT EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Inari Medical, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) un
November 8, 2024	SC 13G/A	NARI / Inari Medical, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t
November 7, 2024	EX-99.1	Joint Filer Agreement EX-99.1 2 d867443dex991.htm EX-99.1 Exhibit 99.1 Joint Filer Agreement The undersigned hereby agree and acknowledge that the statement containing the information required by Schedule 13G, to which this agreement is attached as an exhibit, is filed on behalf of each of them, and any amendments or supplements to the Schedule 13G shall also be filed on behalf of each of them. Dated: 11/7/2024 CVF, LL
November 7, 2024	SC 13G/A	NARI / Inari Medical, Inc. / CVF, LLC - SC 13G/A Passive Investment SC 13G/A 1 d867443dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Inari Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number) February 29, 2024 (Date of Event Which Requires Filing of this Statement) Check t
October 28, 2024	EX-10.1	effective October 1, 2024, by and between Inari Medical, Inc. and Kevin Strange Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), effective as of October 1, 2024, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Kevin Strange (the “Executive”). WHEREAS, the Executive is currently employed as the Senior Vice President of Finance, Accounting, Strategy and Business Development of the Company and, effecti
October 28, 2024	EX-3.2	Amended and Restated Bylaws Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INARI MEDICAL, INC. (a Delaware corporation) (amended and restated as of October 25, 2024) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETINGS 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A
October 28, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 28, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
October 28, 2024	EX-99.1	Inari Medical Reports Third Quarter 2024 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2024 Financial Results IRVINE, CALIFORNIA – October 28, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Fin
July 30, 2024	EX-99.1	Inari Medical Announces Chief Financial Officer Retirement and Succession Plan Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024 Exhibit 99.1 Inari Medical Announces Chief Financial Officer Retirement and Succession Plan Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024 IRVINE, CALIFORNIA – July 30, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and
July 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
July 30, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File
July 30, 2024	EX-99.1	Inari Medical Reports Second Quarter 2024 Financial Results Exhibit 99.1 Inari Medical Reports Second Quarter 2024 Financial Results IRVINE, CALIFORNIA – July 30, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2024. Second Quarter Financia
July 30, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File
May 31, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39293 45-2902923 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 6001 Oak Canyon, Suite 100 92618 Irvine, California (Zip Code)
April 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
April 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Inari Medical, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File
April 30, 2024	EX-99.1	Inari Medical Reports First Quarter 2024 Financial Results Exhibit 99.1 Inari Medical Reports First Quarter 2024 Financial Results IRVINE, CALIFORNIA – April 30, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2024. First Quarter Financial
April 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Inari Medical, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File
April 3, 2024	SC 13G	NARI / Inari Medical, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INARI MEDICAL, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 45332Y109 (CUSIP Number) MARCH 27, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th
March 13, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under § 240.
March 13, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240.
February 29, 2024	EX-97.1	INARI MEDICAL, INC. CLAWBACK POLICY Exhibit 97.1 INARI MEDICAL, INC. CLAWBACK POLICY Inari Medical, Inc. (the “Company”) has adopted this clawback policy (the “Policy”) to address the requirements of the clawback rules found in 17 C.F.R. §240.10D-1 and the related listing rules of The Nasdaq Stock Market, LLC (“Nasdaq” or the “Exchange”). This Policy shall be interpreted to comply with such clawback rules and, to the extent this Pol
February 29, 2024	EX-21.1	Subsidiaries of the registrant Exhibit 21.1 Subsidiaries of Inari Medical, Inc. Subsidiary Name Jurisdiction of Formation Inari Medical International, Inc. Delaware Inari Medical Latin America, Inc. Delaware Inari Medical Australia Pty. Ltd. Australia Inari Medical Distribuicao de Dispositivos Medicos Ltda. Brazil Inari Medical Canada, Inc. Canada Inari Medical Chile SpA Chile Inari Medical Costa Rica, S.A. Costa Rica Inari Med
February 29, 2024	EX-10.16	1, by and between Inari Medical, Inc. and Oak Canyon Creek LLC Exhibit 10.16 SECOND AMENDMENT TO LEASE I.PARTIES AND DATE. This Second Amendment to Lease (“Amendment”) dated July 16, 2021, by and between OAK CANYON CREEK LLC, a Delaware limited liability company (“Landlord”), and INARI MEDICAL, INC., a Delaware corporation (“Tenant”). II.RECITALS. On October 7, 2020, Landlord and Tenant entered into a lease for space in a building located at 6001 Oak Canyon,
February 29, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inari Medical, Inc.
February 29, 2024	EX-10.28	Seventh Amendment and Joinder to the Loan, Guaranty and Security Agreement, dated as of January 24, 2024, by and among Inari Medical Inc., Inari Medical International, Inc., Inari Medical Latin America, Inc., each of the lenders signatory hereto, and Bank of America, N.A., as agent for the lenders. Exhibit 10.28 SEVENTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT This SEVENTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of January 24, 2024, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “IMI”), INARI MEDICAL LATIN AMERICA, INC., a Del
February 29, 2024	EX-10.29	on-Employee Director Compensation Program Exhibit 10.29 INARI MEDICAL, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of January 1, 2024) Eligible Directors (as defined below) on the board of directors (the “Board”) of Inari Medical, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended from time to t
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROMTO Commission File Number 001-3929
February 29, 2024	EX-10.30	Form of Performance Based Restricted Stock Unit Award Agreement Exhibit 10.30 INARI MEDICAL, INC. 2020 INCENTIVE AWARD PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT NOTICE Inari Medical, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Performance-Based Restricted Stock Units (the “PSUs”) described in this Performance-Based Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the
February 28, 2024	EX-99.1	Inari Medical Reports Fourth Quarter 2023 Financial Results Exhibit 99.1 Inari Medical Reports Fourth Quarter 2023 Financial Results IRVINE, CALIFORNIA – February 28, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2023. F
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Inari Medical, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F
February 23, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F
February 14, 2024	EX-99.1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-0789exhibit99.htm JOING FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a
February 14, 2024	SC 13G/A	NARI / Inari Medical, Inc. / Point72 Asset Management, L.P. - INARI MEDICAL, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inari Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
February 13, 2024	SC 13G/A	NARI / Inari Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01172-inarimedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Inari Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 45332Y109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate
February 8, 2024	SC 13G/A	NARI / Inari Medical, Inc. / MILDER DONALD B - SC 13G/A Passive Investment SC 13G/A 1 d763639dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Inari Medical, Inc. (Name of Issuer) Common Stock, par value
February 8, 2024	SC 13G/A	NARI / Inari Medical, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
January 31, 2024	EX-99.1	LIMFLOW CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED DECEMBER 31, 2022 AND AS OF AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 LIMFLOW S.A. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 LIMFLOW CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED DECEMBER 31, 2022 AND AS OF AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 LIMFLOW S.A. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AUDITED CONSOLIDATED FINANCIAL STATEMENTS: Page Independent Auditor's Report 2 Consolidated Balance Sheets 4 Consolidated Statements of Operations and Comprehensive Loss 6 Consolidate
January 31, 2024	8-K/A	Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission
January 31, 2024	EX-99.2	Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.2 Unaudited Pro Forma Condensed Combined Financial Information Introduction On November 15, 2023 (the “Closing Date”), Inari Medical, Inc (“Inari” or the “Company”) consummated the previously announced acquisition of LimFlow S.A (“LimFlow” or the “Seller”). On November 1, 2023, the Company announced that it entered into a share purchase agreement (the “Purchase Agreement”) to acquire Li
January 9, 2024	EX-99.1	Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance Exhibit 99.1 Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance IRVINE, CALIFORNIA – January 9th, 2024 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and estab
January 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Inari Medical, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 15, 2023	EX-99.1	Inari Medical Closes Acquisition of LimFlow Exhibit 99.1 Inari Medical Closes Acquisition of LimFlow IRVINE, Calif., November 15, 2023 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the close of its acquisition of LimFlow S.A., a privately-held pioneer in limb salvage for patients w
November 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Inari Medical, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F
November 2, 2023	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 2, 2023	EX-99.1	Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow Announces Q3 2023 Financial Results Inari to Host Conference Call Today at 1:30 P.M. PT / 4:30 P.M. ET Exhibit 99.1 FOR IMMEDIATE RELEASE Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow Announces Q3 2023 Financial Results Inari to Host Conference Call Today at 1:30 P.M. PT / 4:30 P.M. ET IRVINE, Calif., November 1, 2023 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of pati
November 2, 2023	EX-99.2	This presentation (together with any other statements or information that we may make in connection therewith) may contain are forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, includ Cindy LimFlow Patient Inari Medical Investor Update November 2023 Exhibit 99.2 This presentation (together with any other statements or information that we may make in connection therewith) may contain are forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including anticipated closing of the LimFlow Acquisition (as defined below),
November 2, 2023	EX-10.1	Sixth Amendment and Limited Consent to Loan, Guaranty and Security Agreement, dated November 1, 2023, by and among Inari Medical, Inc., Inari Medical International, Inc., Inari Medical Latin America, Inc., the lenders party thereto and Bank of America, N.A. Exhibit 10.1 Execution Version SIXTH AMENDMENT AND LIMITED CONSENT TO LOAN, GUARANTY AND SECURITY AGREEMENT This SIXTH AMENDMENT AND LIMITED CONSENT TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of November 1, 2023, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “IMI”), INARI MEDIC
November 2, 2023	EX-2.1	Share Purchase Agreement, dated October 31, 2023, by and among Lombardi Sub, LLC, LimFlow S.A., equity holders of LimFlow S.A. and Shareholder Representative Services LLC (solely in its capacity as the Sellers' representative, agent and attorney-in-fact). Exhibit 2.1 EXECUTION VERSION SHARE PURCHASE AGREEMENT by and among LimFlow S.A., the Sellers, Shareholder Representative Services LLC, solely in its capacity as the Seller Representative, Inari Medical, Inc., solely for the purposes of Section 13.16, and Lombardi Sub, LLC DATED AS OF OCTOBER 31, 2023 Table of Contents CONTENTS Page ARTICLE I PURCHASE AND SALE 2 1.1 Purchase and Sale 2 1.2 Purchas
November 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 1, 2023	EX-99.1	Inari Medical Reports Third Quarter 2023 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2023 Financial Results IRVINE, CALIFORNIA – November 1, 2023 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2023. Third Quarter Fin
November 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
September 22, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission
September 22, 2023	EX-10.2	Amended and Restated Employment Agreement, effective September 18, 2023, by and between Inari Medical, Inc. and Mitchell Hill Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of September 18, 2023, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Mitchell Hill (the “Executive”), and amends and restates that certain Employment Agreement entered into between the Company and the Executive, date
September 22, 2023	EX-10.1	Amended and Restated Employment Agreement, effective September 18, 2023, by and between Inari Medical, Inc. and Andrew Hykes Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of September 18, 2023, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Andrew Hykes (the “Executive”), and amends and restates that certain Employment Agreement entered into between the Company and the Executive, dated
September 22, 2023	EX-10.3	Amended and Restated Employment Agreement, effective September 18, 2023, by and between Inari Medical, Inc. and Thomas T. Tu, MD Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of September 18, 2023, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Thomas Tu, M.D. (the “Executive”), and amends and restates that certain Employment Agreement entered into between the Company and the Executive, da
August 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
August 2, 2023	EX-99.1	Inari Medical Reports Second Quarter 2023 Financial Results Exhibit 99.1 Inari Medical Reports Second Quarter 2023 Financial Results IRVINE, CALIFORNIA – August 2, 2023 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2023. Second Quarter Financi
August 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39293 45-2902923 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 6001 Oak Canyon, Suite 100 92618 Irvine, California (Zip Code)
May 19, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File N
May 3, 2023	EX-99.1	Inari Medical Reports First Quarter 2023 Financial Results Exhibit 99.1 Inari Medical Reports First Quarter 2023 Financial Results IRVINE, CALIFORNIA – May 3, 2023 (GLOBE NEWSWIRE) – Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2023. First Quarter Financial an
May 3, 2023	EX-10.2	Amended and Restated Non-Employee Director Compensation Program Exhibit 10.2 INARI MEDICAL, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of May 1, 2023) Eligible Directors (as defined below) on the board of directors (the “Board”) of Inari Medical, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended from time to time,
May 3, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 3, 2023	EX-10.1	dated February 14, 2023, by and between Inari Medical Inc. and Oak Canyon Creek LLC Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. (***) INDICATES THAT INFORMATION HAS BEEN REDACTED. THIRD AMENDMENT TO LEASE I.PARTIES AND DATE. This Third Amendment to Lease (“Amendment”) dated February 14, 2023, by and between OAK CANYON CREEK LLC, a Delaware limited lia
May 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
April 6, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240.
April 6, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under § 240.
February 27, 2023	EX-99	Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results IRVINE, CALIFORNIA – February 27, 2023 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended Decemb
February 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F
February 27, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-392
February 27, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inari Medical, Inc.
February 27, 2023	EX-21	Subsidiaries of the registrant Exhibit 21.1 Subsidiaries of Inari Medical, Inc. Subsidiary Name Jurisdiction of Formation Inari Medical International, Inc. Delaware Inari Medical Europe GmbH Switzerland Inari Medical Asia PTE. LTD. Singapore Inari Medical Canada, Inc. Canada Inari Medical Latin America, Inc. Delaware Inari Medical Australia Pty. Ltd. Australia Inari Medical Distribuicao de Dispositivos Medicos Ltda. Brazil Inar
February 27, 2023	S-8	As filed with the Securities and Exchange Commission on February 27, 2023 As filed with the Securities and Exchange Commission on February 27, 2023 Registration No.
February 27, 2023	EX-10	Fourth Amendment and Joinder to the Loan, Guaranty and Security Agreement, dated as of December 16, 2022. Exhibit 10.28 FOURTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT This FOURTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of December 16, 2022, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “IMI”), INARI MEDICAL LATIN AMERICA, INC., a Dela
February 27, 2023	EX-10	Fifth Amendment and Joinder to the Loan, Guaranty and Security Agreement, dated as of February 6, 2023, by and among Inari Medical, Inc., Inari Medical International, Inc., Inari Medical Latin America, Inc., each of the lenders party thereto, and Bank of America, N.A., as agent for the lenders. Exhibit 10.29 FIFTH AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT This FIFTH AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of February 6, 2023, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “IMI”), INARI MEDICAL LATIN AMERICA, INC., a Delaware corporation (“IMLA” an
February 24, 2023	SC 13G	NARI / Inari Medical Inc / Point72 Asset Management, L.P. - INARI MEDICAL, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45332Y109 (CUSIP Number) February 22, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
February 14, 2023	EX-99.B	Page 13 of 13 EX-99.B 3 d445094dex99b.htm EX-99.B Exhibit 99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited and incorporated by reference to 13G filings made by Macquarie Group Limited and on May 25, 2021. Page 13 of 13
February 14, 2023	EX-99.A	Page 9 of 13 EX-99.A 2 d445094dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”). WHEREAS, th
February 14, 2023	SC 13G/A	NARI / Inari Medical Inc / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Inari Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
February 14, 2023	SC 13G/A	NARI / Inari Medical Inc / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d445094dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inari Medical Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45332Y109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 13, 2023	SC 13G/A	NARI / Inari Medical Inc / MILDER DONALD B - SC 13G/A Passive Investment SC 13G/A 1 d446366dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Inari Medical, Inc. (Name of Issuer) Common Stock, par value
February 13, 2023	SC 13G/A	NARI / Inari Medical Inc / Capital International Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
February 10, 2023	SC 13G/A	NARI / Inari Medical Inc / CVF, LLC - SC 13G/A Passive Investment SC 13G/A 1 d232018dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Inari Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t
February 9, 2023	SC 13G/A	NARI / Inari Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Inari Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 45332Y109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒
February 6, 2023	SC 13G/A	NARI / Inari Medical Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
January 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi
January 27, 2023	EX-10.1	Amended and Restated Employment Agreement, effective January 1, 2023, by and between Inari Medical, Inc. and Andrew Hykes EX-10.1 2 nari-ex101.htm EX-10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of January 1, 2023, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Andrew Hykes (the “Executive”), and amends and restates that certain Employment Agreement entered into between the Company and the
January 10, 2023	EX-99.1	Inari Medical Announces Preliminary 2022 Revenue and 2023 Guidance Exhibit 99.1 Inari Medical Announces Preliminary 2022 Revenue and 2023 Guidance IRVINE, CALIFORNIA – January 10, 2023 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2022 revenue and provid
January 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi
December 19, 2022	EX-10.1	Fourth Amendment and Joinder to the Loan, Guaranty and Security Agreement, dated as of December 16, 2022, by and among Inari Medical, Inc., Inari Medical International, Inc., Inari Medical Latin America, Inc., each of the lenders party thereto, and Bank of America, N.A., as agent for the lenders. Exhibit 10.1 FOURTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT This FOURTH AMENDMENT AND JOINDER TO LOAN, GUARANTY AND SECURITY AGREEMENT (this ?Amendment?), dated as of December 16, 2022, is by and among INARI MEDICAL, INC., a Delaware corporation (the ?Borrower?), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the ?IMI?), INARI MEDICAL LATIN AMERICA, INC., a Delaw
December 19, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F
November 2, 2022	EX-99.1	Inari Medical Reports Third Quarter 2022 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2022 Financial Results IRVINE, CALIFORNIA ? November 2, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2022. Third Quarter Rev
November 2, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F
November 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
September 20, 2022	EX-99.1	Financial Information Unless otherwise indicated, all financial and operational information included herein is as of June 30, 2022. Indications for Use and Publication References Indications for Use and relevant labeling information for all Inari pro Exhibit 99.1 2022 Inari Medical Investor Day Sandy \| Boynton Beach, FL Financial Information Unless otherwise indicated, all financial and operational information included herein is as of June 30, 2022. Indications for Use and Publication References Indications for Use and relevant labeling information for all Inari products included in this presentation are included in the appendix. References to
September 20, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission
August 3, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil
August 3, 2022	EX-99.1	Inari Medical Reports Second Quarter 2022 Financial Results Exhibit 99.1 Inari Medical Reports Second Quarter 2022 Financial Results IRVINE, CALIFORNIA – August 3, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2022. Second Quarter Revenue
August 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
August 3, 2022	EX-10.1	Third Amendment and Joinder to the Loan, Guaranty and Security Agreement, dated as of July 21, 2022 Exhibit 10.1 THIRD AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT This THIRD AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT (this “Amendment”), dated as of July 21, 2022, is by and among INARI MEDICAL, INC., a Delaware corporation (the “Borrower”), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the “Guarantor”), each of the lenders signatory hereto (the “Lenders”), and BANK OF
August 3, 2022	EX-99.1	Inari Medical Announces Leadership Succession Plan Exhibit 99.1 Inari Medical Announces Leadership Succession Plan Drew Hykes to Succeed Bill Hoffman as Chief Executive Officer in January 2023 IRVINE, Calif., August 3, 2022 ? Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that Chief Operating Officer Drew Hy
August 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 27, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File N
May 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File N
May 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
May 4, 2022	EX-99.1	Inari Medical Reports First Quarter 2022 Financial Results Exhibit 99.1 Inari Medical Reports First Quarter 2022 Financial Results IRVINE, CALIFORNIA ? May 4, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2022. First Quarter Revenue and
April 14, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ? 240.
April 14, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ? 240.
March 15, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Inari Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 (State or other jurisdiction of incorporation) (Commission File
March 15, 2022	EX-1.1	Underwriting Agreement, dated March 10, 2022, by and among Inari Medical, Inc. and BofA Securities, Inc. and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein. EX-1.1 2 d322159dex11.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION INARI MEDICAL, INC. (a Delaware corporation) 2,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: March 10, 2022 INARI MEDICAL, INC. (a Delaware corporation) 2,000,000 Shares of Common Stock UNDERWRITING AGREEMENT March 10, 2022 BofA Securities, Inc. Morgan Stanley & Co. LLC as Representatives of the several Underwriters c/o
March 11, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Am EX-FILING FEES Calculation of Filing Fee Tables 424(b)(5) (Form Type) Inari Medical, Inc.
March 11, 2022	424B5	2,000,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-261882 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) 2,000,000 Shares Common Stock We are offering 2,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?NARI.? On March 9, 2022, the last reported sale price of our common stock on the Nasdaq Global
March 10, 2022	424B5	Subject to Completion Preliminary Prospectus Supplement dated March 10, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-261882 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are n
March 1, 2022	EX-99.1	Inari Medical Appoints Robert Warner to Board of Directors Exhibit 99.1 Inari Medical Appoints Robert Warner to Board of Directors IRVINE, CALIFORNIA ? March 1, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the appointment of Mr. Robert Warner to its board of directors. Mr. Warner will serve
March 1, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File
February 23, 2022	EX-21.1	Subsidiaries of the registrant Exhibit 21.1 Subsidiaries of Inari Medical, Inc. Subsidiary Name Jurisdiction of Formation Inari Medical International, Inc. Delaware Inari Medical Europe GmbH Switzerland Inari Medical Asia PTE. LTD. Singapore Inari Medical Canada, Inc. Canada
February 23, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39293 Inari Medical,
February 23, 2022	EX-4.6	Description of Inari Medical, Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.6 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock of Inari Medical, Inc. (the ?Company,? ?we,? ?us,? and ?our?) and certain provisions of our amended and restated certificate of incorporation, as amended from time to time (the ?amended and restated certificate of incorporation?) and amended and restated bylaws, as amended from time to time (the ?amended and re
February 23, 2022	EX-10.25	Form of Restricted Stock Unit Award Agreement pursuant to 2020 Incentive Award Plan - Non-Employee Director Exhibit 10.25 INARI MEDICAL, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE NON-EMPLOYEE DIRECTOR Inari Medical, Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and conditions of the Ina
February 23, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F
February 23, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inari Medical, Inc.
February 23, 2022	EX-99.1	Inari Medical Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Inari Medical Reports Fourth Quarter and Full Year 2021 Financial Results IRVINE, CALIFORNIA ? February 23, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended Decembe
February 23, 2022	EX-10.24	Second Amendment to Loan, Guaranty and Security Agreement, dated as of November 8, 2021 Exhibit 10.24 SECOND AMENDMENT AND LIMITED WAIVER TO LOAN, GUARANTY AND SECURITY AGREEMENT This SECOND AMENDMENT AND LIMITED WAIVER TO LOAN, GUARANTY AND SECURITY AGREEMENT (this ?Amendment?), dated as of November 8, 2021, is by and among INARI MEDICAL, INC., a Delaware corporation (the ?Borrower?), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the ?Guarantor?), each of the lenders si
February 23, 2022	S-8	As filed with the Securities and Exchange Commission on February 23, 2022 As filed with the Securities and Exchange Commission on February 23, 2022 Registration No.
February 23, 2022	EX-10.14	Amended and Restated Non-Employee Director Compensation Program Exhibit 10.14 INARI MEDICAL, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of January 1, 2022) Eligible Directors (as defined below) on the board of directors (the ?Board?) of Inari Medical, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended from time to t
February 14, 2022	SC 13G	NARI / Inari Medical Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inari Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
February 14, 2022	SC 13G	NARI / Inari Medical Inc / MACQUARIE GROUP LTD - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Inari Medical Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
February 11, 2022	SC 13G	NARI / Inari Medical Inc / Capital International Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
February 11, 2022	SC 13G/A	NARI / Inari Medical Inc / MILDER DONALD B - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inari Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul
February 10, 2022	SC 13G/A	NARI / Inari Medical Inc / CVF, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Inari Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
February 10, 2022	SC 13G	NARI / Inari Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Inari Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 45332Y109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ??Rule
February 4, 2022	SC 13G	NARI / Inari Medical Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
January 27, 2022	SC 13G/A	NARI / Inari Medical Inc / US VENTURE PARTNERS X LP - SC 13G/A Passive Investment SC 13G/A 1 tm224259d1sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2021 (Date
January 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi
January 10, 2022	EX-99.1	Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue Exhibit 99.1 Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue IRVINE, CALIFORNIA ? January 10, 2022 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2021 revenue. Preliminary Fourth Quar
December 23, 2021	EX-4.4	Form of Indenture Exhibit 4.4 Inari Medical, Inc. INDENTURE Dated as of , 20 [TRUSTEE] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establ
December 23, 2021	S-3ASR	As filed with the Securities and Exchange Commission on December 23, 2021 Table of Contents As filed with the Securities and Exchange Commission on December 23, 2021 Registration No.
November 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
November 9, 2021	EX-99.1	Inari Medical Reports Third Quarter 2021 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2021 Financial Results IRVINE, CALIFORNIA ? November 9, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its third quarter ended September 30, 2021. Third Quart
November 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2021 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission F
October 1, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 01, 2021 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 1, 2021	EX-99.1	Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors Exhibit 99.1 Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors IRVINE, CALIFORNIA ? October 1, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Mr. Dana G. Mead, Jr. to its board of directors. Mr. Me
September 8, 2021	SC 13D/A	NARI / Inari Medical Inc / Cooperatieve Gilde Healthcare IV U.A. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperat
September 8, 2021	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the time
August 27, 2021	SC 13D/A	NARI / Inari Medical Inc / Cooperatieve Gilde Healthcare IV U.A. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperatieve Gild
August 27, 2021	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the time
August 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
August 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission Fil
August 10, 2021	EX-99.1	Inari Medical Reports Second Quarter 2021 Financial Results Exhibit 99.1 Inari Medical Reports Second Quarter 2021 Financial Results IRVINE, CALIFORNIA ? August 10, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2021.
June 22, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2021 Inari Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39293 45-2902923 (State or Other Jurisdiction of Incorporation) (Commission File
June 22, 2021	EX-99.1	Inari Medical Appoints Outset Medical Executive Rebecca Chambers to Board of Directors Exhibit 99.1 Inari Medical Appoints Outset Medical Executive Rebecca Chambers to Board of Directors IRVINE, CALIFORNIA - June 22, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Ms. Rebecca Chambers to its board
May 28, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization) (
May 24, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 (State or other jurisdiction of incorporation or organization) (C
May 24, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
May 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization) (
May 11, 2021	EX-99.1	Inari Medical Reports First Quarter 2021 Financial Results Exhibit 99.1 Inari Medical Reports First Quarter 2021 Financial Results IRVINE, Calif., May 11, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (?Inari?) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its first quarter ended March 31, 2021. First Qu
May 11, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
April 27, 2021	SC 13D/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* INARI MEDICAL, IN SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperatieve Gild
April 27, 2021	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement.
April 16, 2021	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 16, 2021	DEFA14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 31, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization)
March 31, 2021	EX-10.1	First Amendment to Loan, Guaranty and Security Agreement, dated as of March 30, 2021, by and between Inari Medical, Inc., Inari Medical International, Inc. and each of the lenders signatory thereto and Bank of America, N.A. as agent Exhibit 10.1 FIRST AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT This FIRST AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT (this ?Amendment?), dated as of March 30, 2021, is by and among INARI MEDICAL, INC., a Delaware corporation (the ?Borrower?), INARI MEDICAL INTERNATIONAL, INC., a Delaware corporation (the ?Guarantor?), each of the lenders signatory hereto (the ?Lenders?), and BANK OF
March 17, 2021	144/A	- 144/A OMB APPROVAL OMB Number: 3235-0101 Expires: July 31, 2023 Estimated average burden hours per response 1.
March 16, 2021	SC 13D/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* INARI MEDICAL, IN SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperat
March 11, 2021	S-8	- S-8 - 2021 EVERGREEN As filed with the Securities and Exchange Commission on March 10, 2021 Registration No.
March 9, 2021	EX-10.14	Amended and Restated Non-Employee Director Compensation Program Exhibit 10.14 INARI MEDICAL, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of January 1, 2021) Eligible Directors (as defined below) on the board of directors (the ?Board?) of Inari Medical, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended from time to t
March 9, 2021	EX-10.13	Employment Agreement, dated as of March 5, 2020, by and between Inari Medical, Inc. and Dr. Thomas Tu EX-10.13 3 nari-ex1013763.htm EX-10.13 Exhibit 10.13 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated as of September 1, 2020, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Thomas Tu, M.D. (the “Executive”). WHEREAS, the Company desires to continue the employment of the Executive and the Company and the Executive desire to en
March 9, 2021	EX-10.18	First Amendment to Lease dated March 3, 2021, by and between Inari Medical, Inc. and Oak Canyon Creek LLC Exhibit 10.18 FIRST AMENDMENT TO LEASE I.PARTIES AND DATE. This First Amendment to Lease (?Amendment?) dated March 3, 2021, is by and between OAK CANYON CREEK LLC, a Delaware limited liability company (?Landlord?), and INARI MEDICAL, INC., a Delaware corporation (?Tenant?). II.RECITALS. On October 7, 2020, Landlord and Tenant entered into a lease (?Lease?) for space in a building located at 6001 O
March 9, 2021	EX-99.1	Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results EX-99.1 2 nari-ex9916.htm EX-99.1 Exhibit 99.1 Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results IRVINE, Calif., March 9, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results fo
March 9, 2021	EX-21.1	Subsidiaries of the registrant EX-21.1 7 nari-ex211764.htm EX-21.1 Exhibit 21.1 Subsidiaries of Inari Medical, Inc. Subsidiary Name Jurisdiction of Formation Inari Medical International, Inc. Delaware Inari Medical Europe GmbH Switzerland
March 9, 2021	EX-10.17	Lease Termination Agreement, dated as of October 7, 2020, as modified by that First Amendment to the Lease Termination Agreement dated February 3, 2021, by and between Inari Medical, Inc. and Bake Technology Park LLC EX-10.17 5 nari-ex1017911.htm EX-10.17 Exhibit 10.17 FIRST AMENDMENT TO LEASE TERMINATION AGREEMENT I. PARTIES AND DATE. This First Amendment to Lease Termination Agreement (“Amendment”) dated February 3, 2021, is by and between BAKE TECHNOLOGY PARK LLC, a Delaware limited liability company (“Landlord”), and INARI MEDICAL, INC., a Delaware corporation (“Tenant”). II. RECITALS. On March 6, 2019, La
March 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization)
March 9, 2021	EX-10.8	Form of Restricted Stock Unit Award Agreement pursuant to 2020 Incentive Award Plan – International Exhibit 10.8 INARI MEDICAL, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice NON-US PARTICIPANTS Inari Medical, Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and conditions of the Inari
March 9, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39293 Inari Medical,
February 9, 2021	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. ___)* Inari Medical, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Sta
February 8, 2021	SC 13G	United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Inari Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securi
February 5, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inari Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securit SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inari Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
January 13, 2021	EX-99.1	Inari Medical Reports Preliminary Fourth Quarter 2020 Revenue EX-99.1 2 nari-ex9916.htm EX-99.1 Exhibit 99.1 Inari Medical Reports Preliminary Fourth Quarter 2020 Revenue IRVINE, Calif., Jan 13, 2021 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quar
January 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2021 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizatio
December 23, 2020	SC 13D/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* INARI MEDICAL, IN SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperat
December 4, 2020	SC 13D/A	NARI / Inari Medical, Inc. / Cooperatieve Gilde Healthcare IV U.A. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* INARI MEDICAL, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45332Y109 (CUSIP number) M.O.J.M. Perret Cooperat
November 18, 2020	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizati
November 12, 2020	EX-99.1	Inari Medical Reports Third Quarter 2020 Financial Results Exhibit 99.1 Inari Medical Reports Third Quarter 2020 Financial Results IRVINE, CALIFORNIA – November 12, 2020 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its third quarter ended September 30,
November 12, 2020	8-K	Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizati
November 12, 2020	EX-10.2	Lease Termination Agreement, dated as of October 7, 2020, by and between Inari Medical, Inc. and Bake Technology Park LLC Exhibit 10.2 LEASE TERMINATION AGREEMENT I. PARTIES AND DATE. THIS LEASE TERMINATION AGREEMENT ("Agreement") is made and entered into as of October 7, 2020 , by and between BAKE TECHNOLOGY PARK LLC a Delaware limited liability company ("Landlord"), and INARI MEDICAL, INC., a Delaware corporation (?Tenant?). II. RECITALS. On March 6, 2019, Landlord and Tenant entered into a lease (?Lease?) for spac
November 12, 2020	EX-10.3	Amended and Restated 2020 Employee Stock Purchase Plan Exhibit 10.3 inari medical, inc. AMENDED AND RESTATED 2020 EMPLOYEE STOCK PURCHASE PLAN Article I. PURPOSE The purposes of this Inari Medical, Inc. Amended and Restated 2020 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the ?Plan?) are to assist Eligible Employees of Inari Medical, Inc., a Delaware corporation (the ?Company?), and the other Participating Compani
November 12, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
November 12, 2020	EX-10.1	Lease Agreement, dated as of October 7, 2020, by and between Inari Medical, Inc. and Oak Canyon Creek LLC Exhibit 10.1 LEASE BETWEEN OAK CANYON CREEK LLC AND INARI MEDICAL, INC. LEASE THIS LEASE is made as of October 7, 2020, by and between OAK CANYON CREEK LLC, a Delaware limited liability company, hereafter called ?Landlord,? and INARI MEDICAL, INC., a Delaware corporation, hereafter called ?Tenant.? ARTICLE 1. BASIC LEASE PROVISIONS Each reference in this Lease to the ?Basic Lease Provisions? shall
October 22, 2020	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizatio
October 13, 2020	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization
September 17, 2020	8-K	Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 15, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizat
September 17, 2020	EX-99.1	Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer Exhibit 99.1 Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer IRVINE, CALIFORNIA – September 17, 2020 (GLOBE NEWSWIRE) - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the promotion of Drew Hykes to Chief Opera
September 11, 2020	EX-10.1	Loan, Guaranty and Security Agreement, dated as of September 4, 2020, by and among Inari Medical, Inc., Inari Medical International, Inc. and Bank of America, N.A Exhibit 10.1 LOAN, GUARANTY AND SECURITY AGREEMENT Dated as of September 4, 2020 INARI MEDICAL, INC., and CERTAIN SUBSIDIARIES FROM TIME TO TIME JOINED HERETO, as Borrowers, INARI MEDICAL INTERNATIONAL, INC., and CERTAIN SUBSIDIARIES FROM TIME TO TIME JOINED HERETO, as Guarantors, BANK OF AMERICA, N.A., as Agent, Sole Lead Arranger and Sole Bookrunner 1333152378 Table of Contents Page Section 1. D
September 11, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 4, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organizati
August 11, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39293 Inari Medical, Inc.
August 11, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2020 INARI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-39293 45-2902923 ( State or other jurisdiction of incorporation or organization

NARI / Inari Medical, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)